Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study

BACKGROUND. The 21-gene Oncotype DX Recurrence Score assay is a validated assay to help decide the appropriate treatment for estrogen receptor-positive (ER+), early-stage breast cancer (EBC) in the adjuvant setting. The choice of adjuvant treatments might vary considerably in different countries acc...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Gligorov, Joseph, Pivot, Xavier B., Jacot, William, Naman, Hervé L., Spaeth, Dominique, Misset, Jean-Louis, Largillier, Rémy, Sautiere, Jean-Loup, de Roquancourt, Anne, Pomel, Christophe, Rouanet, Philippe, Rouzier, Roman, Penault-Llorca, Frederique M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2015
Aiheet:
Breast Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4524752/
https://ncbi.nlm.nih.gov/pubmed/26112003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0467
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia